KCNAB2 encodes a regulatory beta subunit of voltage-gated potassium (Kv) channels that plays crucial roles in neuronal excitability and cellular regulation 1. The protein promotes potassium channel inactivation through a mechanism that does not involve physical pore obstruction, specifically targeting Kv1.4 and Kv1.5 alpha subunit-containing channels 2. KCNAB2 also possesses NADPH-dependent aldoketoreductase activity, catalyzing the reduction of various aldehyde and ketone substrates. In neurological function, KCNAB2 deletion in mice results in associative memory impairments and amygdala hyperexcitability, demonstrating reduced slow afterhyperpolarization and increased neuronal excitability 2. Clinically, KCNAB2 haploinsufficiency is significantly associated with epilepsy in 1p36 deletion syndrome patients, with 89% of KCNAB2-deleted patients exhibiting seizures or epileptiform activity compared to 27% of non-deleted patients 1. The gene also functions as a tumor suppressor in non-small cell lung cancer, where its downregulation correlates with poor prognosis and reduced immune infiltration 34. KCNAB2 overexpression inhibits cancer cell growth and M2 macrophage polarization by inactivating the PI3K/AKT pathway 5. Additionally, KCNAB2 expression is regulated by FTO-mediated m6A methylation, adding another layer of post-transcriptional control 5.